Sanofi (NASDAQ:SNY) Given Consensus Rating of “Hold” by Analysts

Sanofi (NASDAQ:SNY) has been assigned an average recommendation of “Hold” from the fifteen brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation, three have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $49.50.

Several research analysts have weighed in on SNY shares. Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 29th. Morgan Stanley set a $49.00 price target on shares of Sanofi in a research report on Wednesday, July 8th. Finally, Weiss Ratings cut Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, August 3rd.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Physician Wealth Advisors Inc. grew its stake in Sanofi by 180.5% in the 1st quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock valued at $28,000 after acquiring an additional 379 shares during the last quarter. Western Wealth Management LLC acquired a new position in Sanofi during the first quarter worth about $29,000. Leonteq Securities AG lifted its holdings in shares of Sanofi by 95.8% in the first quarter. Leonteq Securities AG now owns 607 shares of the company’s stock valued at $29,000 after purchasing an additional 297 shares in the last quarter. Measured Wealth Private Client Group LLC purchased a new stake in shares of Sanofi in the third quarter valued at about $29,000. Finally, Palisade Asset Management LLC acquired a new stake in shares of Sanofi in the third quarter valued at approximately $30,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Sanofi Trading Down 0.3%

NASDAQ:SNY opened at $44.33 on Friday. Sanofi has a 1 year low of $40.89 and a 1 year high of $52.68. The company has a debt-to-equity ratio of 0.21, a quick ratio of 0.64 and a current ratio of 0.99. The stock has a fifty day moving average price of $43.89 and a two-hundred day moving average price of $44.71. The stock has a market capitalization of $107.47 billion, a price-to-earnings ratio of 23.21, a PEG ratio of 1.36 and a beta of 0.35.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, July 30th. The company reported $2.41 EPS for the quarter. The company had revenue of $13.36 billion for the quarter. Sanofi had a net margin of 8.66% and a return on equity of 14.19%. Sanofi’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.24 earnings per share. As a group, sell-side analysts anticipate that Sanofi will post 5.01 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.